Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renshen Yangrong Wan is a traditional Chinese medicine (TCM) formula produced by Liaoning Jindan Pharmaceutical. It is primarily indicated for the replenishment of Qi and the nourishment of blood, specifically targeting syndromes characterized by deficiencies in both. Clinical applications include the treatment of physical exhaustion, palpitations, shortness of breath, insomnia, cold extremities, and poor appetite. The formula is a complex mixture of herbal ingredients, typically including *Panax ginseng* (Renshen), *Atractylodes macrocephala* (Baizhu), *Poria cocos* (Fuling), *Glycyrrhiza uralensis* (Gancao), *Angelica sinensis* (Danggui), *Rehmannia glutinosa* (Shudihuang), *Paeonia lactiflora* (Baishao), *Cinnamomum cassia* (Rougui), *Citrus reticulata* (Chenpi), *Polygala tenuifolia* (Yuanzhi), and *Schisandra chinensis* (Wuweizi). It is an approved and marketed product in China, often used for recovery after illness or for chronic fatigue states.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Renshen Yangrong Wan.